• Pharming held its 1Q 2026 results call on May 7 with CEO Fabrice Chouraqui, Chief Commercial Officer Leverne Marsh, Chief Medical Officer Anurag Relan, Chief Financial Officer Kenneth Lynard; analysts on the line included Jefferies, Oppenheimer, Van Lanschot Kempen, H.C. Wainwright, Canaccord Genuity, RBC, First Berlin.
• Revenue came in at USD 72.4 million, down 8% year on year; RUCONEST revenue fell 15% on an expected 8% hit from US specialty-pharmacy inventory drawdown plus a 3% impact from planned exit from ex-US markets, with management flagging further pressure in Q2 before a return to growth in H2 as inventory rebuilds.
• Joenja revenue rose 34% to USD 14.1 million globally; US paid patients reached 127, up 25% year on year, with an 85% fill rate, while management pointed to Germany as first European launch later in Q2 and Japan launch targeted for August.
• Company reaffirmed 2026 revenue guidance of USD 405 million to USD 425 million; CFO cited timing of US pediatric Joenja label expansion as key swing factor, with guidance now including pediatric revenue later in year on a conservative six-month FDA review assumption.
• On Joenja pediatric expansion, CMO said Pharming resubmitted sNDA in April for 40 mg and 50 mg doses with an FDA decision expected in six months or sooner; a separate summer submission is planned for lowest doses, with no additional clinical trial required.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharming Group NV published the original content used to generate this news brief on May 15, 2026, and is solely responsible for the information contained therein.